II Ivivi Technologies, Inc.

Ivivi Technologies, Inc.�s (AMEX: II) non-invasive, pulsed electromagnetic field (PEMF) technology increased tensile strength in a standard wound model in rats by 59% after 21 days, researchers reported in the August 2007 journal of Plastic and Reconstructive Surgery. The study was conducted at the Montefiore Medical Center, in The Teaching Hospital of the Albert Einstein College of Medicine in New York. PEMF signals have accelerated the physiological processes involved in healing in multiple clinical studies. �PEMF signals accelerate biomechanical wound healing. These wounds healed faster and were stronger, earlier, than those that weren�t treated,� said Dr. Berish Strauch, of the Department of Plastic and Reconstructive Surgery at Albert Einstein, in whose lab the study was done. �This study represents the first objective data on the effect of PEMF on healing rates of cutaneous wounds at the cellular level. Although the mechanisms of action are not fully known, previous studies have shown that PEMF enhances the production of wound healing factors that reduce the time of the inflammatory phase as well as accelerates the production of the animal�s own growth factors including Vascular Endothelial Growth Factor (VEGF), which modulates new blood vessel growth. This study shows that a specifically configured PEMF signal yields the best result.� �As we get a clearer picture of the transduction properties of the physiological pathways involved in tissue repair, we can configure new PEMF signals,� said Dr. Arthur Pilla, Professor of Biomedical Engineering at Columbia University, Ivivi Science Director, and a co-author of the study. �We are increasingly able to fine-tune the configuration of PEMF signals to achieve a more optimal �dose� for different indications, as evidenced in this study.� Dr. Pilla invented the bone-growth stimulator, an early medical application of PEMF technology. �If a patient can be discharged earlier after surgery, not only can that patient return to an active lifestyle more rapidly, but healthcare costs can be reduced,� commented Andre� DiMino, Vice Chairman and Co-CEO of Ivivi Technologies, Inc. �Thus, if we can increase the strength of a wound at an earlier stage in the postoperative period, we can offer an absolute improvement on patient outcomes with a simple non-invasive technology with no known side effects.� About The Study The study involved 100 rats, each with a linear skin incision on their dorsum that was subsequently sutured and treated with non-invasive PEMF signals. The study was prospective, placebo-controlled and double blinded and designed to test different PEMF signal configurations for 21 days. Four different signals were used targeting the calcium/calmodulin pathway which is at the start of the anti-inflammatory and growth factor stages of tissue repair. PEMF has been shown to accelerate the binding of calcium to calmodulin. At the end of the 21 day period, one specific signal had the most significant effect on wound repair, demonstrating a 59% increase in wound tensile strength compared to control, leading researchers to conclude that exposing wounds to PEMF of very specific configurations accelerated wound repair in the early, most critical phases of healing in this animal model. About Ivivi Technologies, Inc. Based in Northvale, NJ, Ivivi Technologies, Inc. is a medical technology company focusing on designing, developing and commercializing its proprietary electrotherapeutic technology platform. Ivivi�s research and development activities are focused specifically on pulsed electromagnetic field, or PEMF, technology, which, by creating a therapeutic electrical current in injured soft tissue, stimulates biochemical and physiological healing processes to help repair the injured tissue and reduce related pain and inflammation. The Company�s Electroceuticals� have been used in non-invasive treatments for a wide array of conditions, including chronic wounds, pain and edema following plastic and reconstructive surgery and chronic inflammatory disorders. Forward-Looking Statements This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, the Company�s limited operating history, history of significant and continued operating losses and substantial accumulated earnings deficit, difficulties with its financial accounting controls, the failure of the market for the Company�s products to continue to develop, the inability for customers to receive third party reimbursement, the inability to obtain additional capital, the inability to protect the Company�s intellectual property, the loss of any executive officers or key personnel or consultants, competition, changes in the regulatory landscape or the imposition of regulations that affect the Company�s products and other risks detailed from time to time in the Company�s filings with the Securities and Exchange Commission, including the Company�s registration statement on Form SB-2. The Company assumes no obligation to update the information contained in this press release.